p. 1−15
2090-7125
Vol.21/No.1
p. 16−32
2090-7125
Vol.21/No.1
p. 33−42
2090-7125
Vol.21/No.1
p. 43−52
2090-7125
Vol.21/No.1
p. 53−65
2090-7125
Vol.21/No.1
p. 66−81
2090-7125
Vol.21/No.1
p. 82−94
2090-7125
Vol.21/No.1
p. 95−108
2090-7125
Vol.21/No.1
p. 109−115
2090-7125
Vol.21/No.1
p. 116−130
2090-7125
Vol.21/No.1
p. 131−138
2090-7125
Vol.21/No.1
p. 139−144
2090-7125
Vol.21/No.1
p. 145−161
2090-7125
Vol.21/No.1
p. 162−175
2090-7125
Vol.21/No.1
p. 176−190
2090-7125
Vol.21/No.1
p. 191−201
2090-7125
Vol.21/No.1
p. 202−207
2090-7125
Vol.21/No.1
p. 208−218
2090-7125
Vol.21/No.1
150 pg/ml and serum bAP > 27 ng/ml.
The serum level of intact osteocalcin was measured for the control group and for all hemodialysed patients.
The results revealed highly significant stastical differences in serum level of intact osteocalcin between all patients group and the control subjects being lower in control group.
Also, the results revelaed that 30% of all patients group had adynamic bone disease and comparison between serum level of intact osteocalcin in adynamic bone disease group versus other patients group was highly significant, being higher in other patients group.
There was no significant difference between adynamic bone disease patients and other patients as regard serum phosphorus, and serum calcium but there was a sigificant difference as regard age, while highly significant difference as regard sex, duration of hemodialysis, serum intact osteocalin, iPTH and bAP.
These results suggest that combined estimation of serum iPTH, serum intact osteocalcin, and bAP can provide a useful information on the bone status in uremic patients and repesent reliable non invasive diagnostic tools for the prediction of adynamic bone disease. ]]>
p. 219−232
2090-7125
Vol.21/No.1